Erstautorenschaften:

​

Dold M, Bartova L, Fugger G, Mitschek MMM, Fabbri C, Serretti A, Mendlewicz J, Souery D, Zohar J, Montgomery S, Kasper S, 2022. Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. Journal of Affective Disorders 296, 485-492.

 

Dold M, Bartova L, Fugger G, Kautzky A, Mitschek MMM, Fabbri C, Montgomery S, Zohar J, Souery D, Mendlewicz J, Serretti A, Kasper S, 2021. Melancholic features in major depression - a European multicenter study. Progress in Neuropsychopharmacology & Biological Psychiatry, 110285.

​

Dold M, Bartova L, Fugger G, Mitschek MMM, Kautzky A, Frey R, Montgomery S, Zohar J, Mendlewicz J, Souery D, Fabbri C, Serretti A, Kasper S, 2020. Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. European Neuropsychopharmacology 41, 70-80.

​

Dold M, Bartova L, Kasper S, 2020. Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic augmentation treatment. International Journal of Neuropsychopharmacology 23, 440-445.

​

Dold M, Kasper S, 2020. Dose-response relationship of selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica 142, 427-429.

      

Dold M, Bartova L, Kautzky A, Porcelli S, Montgomery S, Zohar J, Mendlewicz J, Souery D, Serretti A, Kasper S, 2019. Psychotic features in patients with major depressive disorder - a report from the European Group for the Study of Resistant Depression. Journal of Clinical Psychiatry 80, 17m12090.

 

Dold M, Bartova L, Kautzky A, Serretti A, Porcelli S, Souery D, Mendlewicz J, Montgomery S, Zohar J, Kasper S, 2018. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - results from a European multicenter study. European Neuropsychopharmacology 28, 1305-1313.

​

Dold M, Bartova L, Fugger G, Kautzky A, Souery D, Mendlewicz J, Papadimitriou GN, Dikeos D, Ferentinos P, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S, 2018. Major depression and the degree of suicidality: results of the European Group for the Study of Resistant Depression (GSRD). International Journal of Neuropsychopharmacology 21, 539-549.

 

Dold M, Bartova L, Mendlewicz J, Souery D, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S, 2018. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatrica Scandinavica 137, 401-412.

 

Dold M, Bartova L, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S, 2018. Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - findings from a European multicenter study. Journal of Affective Disorders 227, 254-259.

 

Dold M, Bartova L, Rupprecht R, Kasper S, 2017. Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials. Psychotherapy and Psychosomatics 86, 283-291.

 

Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S, 2017. The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - results from a cross-sectional European multicenter study. European Neuropsychopharmacology 27, 625-632.

 

Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S, 2017. Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. Journal of Psychiatric Research 91, 1-13.

 

Dold M, Kasper S, 2017. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice 21, 13-23.

 

Dold M, Kautzky A, Bartova L, Rabl U, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S, 2016. Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - a pharmacoepidemiological cross-sectional multicenter study. European Neuropsychopharmacology 26, 1960-1971.

 

Dold M, Tardy M, Samara MT, Li C, Kasper S, Leucht S, 2016. Are all first-generation antipsychotics equally effective in treating schizophrenia? a meta-analysis of randomized, haloperidol-controlled trials. The World Journal of Biological Psychiatry 17, 210-220.

 

Dold M, Kasper S, 2015. Increasing placebo response in antipsychotic trials: a clinical perspective. Evidence-Based Mental Health 18, 77-79.

 

Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S, 2015. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Research 166, 187-193.

 

Dold M, Aigner M, Lanzenberger R, Kasper S, 2015. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology 18, pyv047.

 

Dold M, Aigner M, Klabunde M, Treasure J, Kasper S, 2015. Second-generation antipsychotic drugs in anorexia nervosa - a meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics 84, 110-116.

 

Dold M, Samara MT, Li C, Tardy M, Leucht S, 2015. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database of Systematic Reviews, CD009831.

​

Dold M, Leucht S, 2014. Pharmakotherapie der therapieresistenten Schizophrenie. PSYCH up2date 8, 281-296.

 

Dold M, Leucht S, 2014. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evidence-Based Mental Health 17, 33-37.

                     

Dold M, Li C, Tardy M, Gillies D, Leucht S, 2013. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and cochrane review of randomized controlled trials. European Neuropsychopharmacology 23, 1023-1033.

​

Dold M, Aigner M, Lanzenberger R, Kasper S, 2013. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology 16, 557-574.

​

Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S, 2012. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews, CD006391.

​

Dold M, Demal U, Lenz G, Schiepek G, Aigner M, 2012. Beeinflussung des Behandlungsergebnisses einer stationären Psychotherapie von Zwangsstörungen durch den Ausprägungsgrad der Instabilität im Therapieverlauf. Neuropsychiatrie 26, 23-27.

​

Dold M, Leucht S, 2012. Psychopharmaka sind besser als ihr Ruf. Clinicum neuropsy 2/2012, 26-29.

 

Dold M, Aigner M, Lanzenberger R, Kasper S, 2011. Effektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen - eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien. Fortschritte der Neurologie Psychiatrie 79, 453-466.

 

Dold M, Lenz G, Demal U, Aigner M, 2010. Monitoring- und Feedback-Systeme in der Psychotherapie. Psychotherapie Forum 18, 208-214.

​

Dold M, Aigner M, 2010. Analgetikaabusus - Medication Overuse Headache. Jatros Neurologie & Psychiatrie 7/2010, 12-16.

 

Dold M, Aigner M, 2009. Neuroimaging der verschiedenen Symptomdimensionen der Zwangsstörung. Neuropsychiatrie 23, 193-205.

​

Dold M, Unger A, Demal U, Lenz G, Schiepek G, Aigner M, 2009. Tägliches Therapiemonitoring im Rahmen der stationären Verhaltenstherapie von Zwangsstörungen - ein Fallbericht. Psychiatrie & Psychotherapie 5, 110-113.

​

Ko-Autorenschaften:

​

Fugger G, Bartova L, Fabbri C, Fanelli G, Zanardi R, Dold M, Kautzky A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Serretti A, Kasper S, 2022. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. Journal of Affective Disorders 312, 225-234.

 

Bartova L, Dold M, Volz HP, Seifritz E, Möller HJ, Kasper S, in press. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. European Archives of Psychiatry and Clinical Neuroscience.

 

Fugger G, Bartova L, Fabbri C, Fanelli G, Dold M, Swoboda MMM, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S, 2022. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. European Archives of Psychiatry and Clinical Neuroscience 272, 715-727.

 

Fugger G, Bartova L, Dold M, Fabbri C, Fanelli G, Zanardi R, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S, 2022. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. Progress in Neuropsychopharmacology & Biological Psychiatry 114, 110480.

​

Bartova L, Fugger G, Dold M, Kautzky A, Swoboda MMM, Rujescu D, Zohar J, Souery D, Mendlewicz J, Montgomery S, Fabbri C, Serretti A, Kasper S, 2022. The choice of either quetiapine or aripiprazole as augmentation treatment in a European naturalistic sample of patients with major depressive disorder. International Journal of Neuropsychopharmacology 25, 118-127.

 

Bartova L, Fugger G, Dold M, Swoboda MMM, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S, 2021. Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. Journal of Psychiatric Research 141, 167-175.

 

Bartova L, Dold M, Fugger G, Kautzky A, Mitschek MMM, Weidenauer A, Hienert MG, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S, 2021. Sex-related effects in major depressive disorder: results of the European Group for the Study of Resistant Depression. Depression and Anxiety 38, 896-906.

​

Mitschek MMM, Vanicek T, Unterholzner J, Kraus C, Weidenauer A, Naderi-Heiden A, Frey R, Silberbauer L, Gryglewski G, Papageorgiou K, Winkler D, Dold M, Kasper S, Praschak-Rieder N, Bartova L, 2021. How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal of Affective Disorders Reports 5, 100186.

​

Bartova L, Dold M, Fugger G, Kautzky A, Mitschek MMM, Weidenauer A, Handschuh PA, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S, 2021. The role of relationship status in major depressive disorder: results of the European Group for the Study of Resistant Depression. Journal of Affective Disorders 286, 149-157.

 

Kautzky A, Möller HJ, Dold M, Bartova L, Seemüller F, Laux G, Riedel M, Gaebel W, Kasper S, 2021. Combining machine learning algorithms for depression of antidepressant treatment response. Acta Psychiatrica Scandinavica 143, 36-49.

 

Fugger G, Dold M, Bartova L, Mitschek MM, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Fabbri C, Frey R, Kasper S, 2020. Clinical correlates and outcome of major depressive disorder and comorbid migraine: a report of the European Group for the Study of Resistant Depression. International Journal of Neuropsychopharmacology 23, 571-577.

 

Huhn M, Leucht C, Rothe P, Dold M, Heres S, Bornschein S, Schneider-Axmann T, Hasan A, Leucht S, 2021. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. European Archives of Psychiatry and Clinical Neuroscience 271, 293-302.

 

Pjrek E, Friedrich ME, Cambioli L, Dold M, Jäger F, Komorowski A, Lanzenberger R, Kasper S, Winkler D, 2020. The efficacy of light therapy in the treatment of seasonal affective disorder: a meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics 89, 17-24.

 

Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S, 2019. Results of the European group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. The World Journal of Biological Psychiatry 20, 427-448.

 

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S, 2019. Major depression and comorbid diabetes - findings from the European Group for the Study of Resistant Depression. Progress in Neuropsychopharmacology & Biological Psychiatry 94, 109638.

 

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S, 2019. Comorbid hypertension in patients with major depressive disorder - results from a European multicenter study. European Neuropsychopharmacology 29, 777-785.

 

Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, Souery D, Montgomery S, Albani D, Raimondi I, Dikeos D, Rujescu D, Uher R, Lewis CM, Mendlewicz J, Serretti A, 2019. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. The British Journal of Psychiatry 241, 36-41.

 

Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Dikeos D, Rujescu D, Kasper S, 2019. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatrica Scandinavica 139, 78-88.

 

Bartova L, Papageorgiou K, Milenkovic I, Dold M, Weidenauer A, Willeit M, Winkler D, Kasper S, 2018. Rapid antidepressant effect of S-ketamine in schizophrenia. European Neuropsychopharmacology 28, 980-982.

 

Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio GM, Fabbri C, Mendlewicz J, Racagni G, Kasper S, Riva MA, Drago F, 2018. International Union of Basic and Clinical Pharmacology CIV: the neurobiology of treatment-resistant depression: from antidepressant classifications to novel pharmacological targets. Pharmacological Reviews 70, 475-504.

 

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S, 2018. Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). European Neuropsychopharmacology 28, 752-760.

 

Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, Zohar J, Mendlewicz J, 2018. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. Journal of Affective Disorders 227, 777-786.

 

Kautzky A, Dold M, Bartova L, Spies M, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Kasper S, 2018. Refining prediction in treatment-resistant depression: results of machine learning analyses in the TRD III sample. Journal of Clinical Psychiatry 79, 16m11385.

 

Bartova L, Weidenauer A, Dold M, Naderi-Heiden A, Kasper S, Willeit M, Praschak-Rieder N, 2017. Robust antidepressant effect following alternating intravenous racemic ketamine and electroconvulsive therapy in treatment-resistant depression: a case report. Journal of ECT 33, e31-e32.

 

Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S, 2016. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73, 199-210.

 

Bartova L, Dold M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, 2015. Ultra-high-dose long-acting injectable aripiprazole in chronic refractory schizophrenia: a case report. Journal of Clinical Toxicology 5, 270.

 

Leucht S, Helfer B, Dold M, Kissling W, McGrath J, 2015. Lithium for schizophrenia. Cochrane Database of Systematic Reviews, CD003834.

 

Tardy M, Dold M, Engel RR, Leucht S, 2014. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews, CD009227.

 

Tardy M, Dold M, Engel RR, Leucht S, 2014. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews, CD009396.

 

Huhn M, Tardy M, Spineli LM, Kissling W, Förstl H, Pitschel-Walz G, Leucht C, Samara M, Dold M, Davis JM, Leucht S, 2014. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 71, 706-715.

​

Leucht S, Helfer B, Dold M, Kissling W, McGrath J, 2014. Carbamazepine for schizophrenia. Cochrane Database of Systematic Reviews, CD001258.

 

Schiepek G, Tominschek I, Heinzel S, Aigner M, Dold M, Unger A, Lenz G, Windischberger C, Moser E, Plöderl M, Lutz J, Meindl T, Zaudig M, Pogarell O, Karch S, 2013. Discontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated fMRI and daily self-reports. PLOS One 8, e71863.

​

Leucht S, Hierl S, Kissling W, Dold M, Davis JM, 2012. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. The British Journal of Psychiatry 200, 97-106.